Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 8/20 | 0.44 |
| ▸ | HTR2C | P28335 | 8/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8520611 | 0.73 | HTR1A (0.46) | HTR7DRD2HTR1ADRD3MEN1 | |
| SCHEMBL7205499 | 0.70 | HTR2A (0.48) | HTR7HTR2AHTR2CDRD2HTR1A | |
| Fumaric Acid SCHEMBL7205491 | 0.68 | DRD2 (0.55) | HTR7HTR2AHTR2CDRD2HTR1A | |
| Fumaric Acid SCHEMBL7205504 | 0.68 | DRD2 (0.55) | HTR7HTR2AHTR2CDRD2HTR1A | |
| SCHEMBL2113444 | 0.63 | ALDH1A1 (0.64) | HTR7TSHRMEN1ALDH1A1KMT2A | |
| SCHEMBL10838542 | 0.63 | ALDH1A1 (0.60) | HTR2AHTR2CDRD2HTR1ASLC6A4 | |
| SCHEMBL15105965 | 0.62 | HTR7 (0.59) | HTR7HTR2AHTR2CDRD2HTR1A | |
| SCHEMBL5011344 | 0.62 | HPGD (0.67) | TSHRMEN1ALDH1A1KMT2AABCB1 | |
| SCHEMBL7205882 | 0.62 | DRD2 (0.49) | HTR7HTR2AHTR2CDRD2HTR1A | |
| SCHEMBL5009458 | 0.62 | ALDH1A1 (0.61) | HTR7HTR2AHTR2CDRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613901-B2 | For therapy and prophylaxis of neuropsychochological disorders such as schizophrenia and other central nervous system diseases | NEUROGEN CORPORATION | 2003-09-02 | — | — | US | disclosed |
| US-20020143019-A1 | 2-aminoalkylaminoquinolines as dopamine D4 ligands | NEUROGEN CORPORATION | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143019-A1 | 2-aminoalkylaminoquinolines as dopamine D4 ligands | SLC6A3, DRD4, ADRA2C | HTR7 102/4885HTR2A 80/4885HTR2C 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.